Irritable Bowel Syndrome – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis – IBS Without Diarrhea (Including IBS-Constipation) – (US)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation predominant, diarrhea predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers IBS-C and IBS without diarrhea. Limited treatment options are available, and only a few drugs have secured FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceutical’s Trulance), and bicyclic fatty acids (Takeda’s Amitiza and its generic, lubiprostone by Par), all of which are moderately effective treating the disease. Zelnorm, a 5-HT4 receptor agonist, was withdrawn from the market in 2007 but was recently relaunched for women with IBS-C who are younger than 65.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-C (including IBS without diarrhea)? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C (including IBS without diarrhea) patients?
  • Have Linzess and Trulance continued to gain patient share? Following its relaunch, how has Zelnorm been re-incorporated into the treatment algorithm? What is the uptake of the newly launched generic, lubiprostone, in the treatment algorithm?
  • What percentage of IBS-C patients receive drug therapy within 365 days of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of IBS-C patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Allergan, Synergy Pharmaceuticals, Takeda, Alfasigma

Key drugs: Linzess, Trulance, Amitiza, lubiprostone (generic), Zelnorm, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic antidepressants

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Irritable Bowel Syndrome - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS-Constipation) - (US)
    • Treatment-Algorithms-Claims-Data-Analysis-IBS-C-US-January-2022
    • Treatment Algorithms Claims Data Analysis IBS - Constipation US 2022 Dashboard

Login to access report

launch Related Market Assessment Reports